There is interest in stem cell based therapies for the treatment of idiopathic pulmonary fibrosis (IPF).
These types of therapies are still in their early stages of clinical trials and further research is needed to determine the benefits and/or risks that they may have on lung conditions such as IPF. Such therapies will not be clinically available to patients until the safety and the effectiveness have been rigorously documented and scientifically proven. Currently, the only option for patients to access this type of therapy is through participation in approved clinical trials, in which patients are closely monitored and the potential benefits and harm can be objectively assessed. All treatment therapies should be discussed with the patient’s doctor prior to participation. There are risk involved in participating in clinical trials and there is no guarantee of a benefit.
A list of current clinical trials for which patients might be eligible can be found at the Clinical Trial Registry: www.clinicaltrialsregister.eu/ctr-search/search